Next-Generation Targeted Molecular Therapies in Immune-Mediated Inflammatory Diseases
Advanced Pharmaceutical Bulletin · 15.06.2026 · 16 (2) · 332-342
DOI: 10.34172/apb.46844 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Pharmaceutical Bulletin, online erschienen am 10.05.2026. Verfasst von Mostafa Akbarzadeh-Khiavi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Die Arbeit nennt 155 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Immune-mediated inflammatory diseases (IMIDs) are chronic disorders characterized by dysregulated immunity and loss of self-tolerance. Although significant progress has been made in the management of IMIDs, challenges such as drug resistance, immunogenicity, and limited accessibility continue to impede clinical outcomes. Achieving sustained remission necessitates a transition toward precision medicine that addresses fundamental disease mechanisms. This study examines recent advances in molecular interventions, including cytokine inhibitors, kinase modulators, and B-cell therapies, and emphasizes how these approaches improve remission rates and reduce relapses. Additionally, emerging platforms such as RNA therapeutics, nanomedicine, and chimeric antigen receptor (CAR) cell therapies are discussed, with a focus on their potential to enhance efficacy and prolong clinical response duration. Integrating these innovations with artificial intelligence to identify therapeutic targets, predict patient responses, and optimize drug development is essential to realizing truly personalized, more successful treatments for IMIDs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
- Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
- Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
ORCID-Profile: Mostafa Akbarzadeh-Khiavi, Azam Safary
Zitieren
APA
Akbarzadeh-Khiavi, M., Olfati, A. H., & Safary, A. (2026). Next-Generation Targeted Molecular Therapies in Immune-Mediated Inflammatory Diseases. Advanced Pharmaceutical Bulletin, 16(2), 332-342. https://doi.org/10.34172/apb.46844
Vancouver
Akbarzadeh-Khiavi M, Olfati AH, Safary A. Next-Generation Targeted Molecular Therapies in Immune-Mediated Inflammatory Diseases. Advanced Pharmaceutical Bulletin. 2026;16(2):332-342. doi:10.34172/apb.46844
BibTeX
@article{AkbarzadehKhiavi2026,
author = {Akbarzadeh-Khiavi, Mostafa and Olfati, Amir-Hossein and Safary, Azam},
title = {Next-Generation Targeted Molecular Therapies in Immune-Mediated Inflammatory Diseases},
journal = {Advanced Pharmaceutical Bulletin},
year = {2026},
volume = {16},
number = {2},
pages = {332--342},
doi = {10.34172/apb.46844}
}
EUVIMED